Aloxi web

Anticipatory Nausea & Vomiting

The third type of chemotherapy-induced nausea and vomiting (CINV) is called anticipatory CINV.¹

Anticipatory CINV often occurs before starting a new chemotherapy cycle in patients who have experienced uncontrolled CINV with prior treatments. Anticipatory CINV develops as a conditioned (i.e., Pavlovian or learned) response.²

This type of CINV tends to happen in response to triggers associated with the therapy environment such as site and smells of the room or clinic. The pattern of anticipatory CINV typically begins after several courses of treatment.³

References

Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2002; 6:94-102.
Gralla R. Management of nausea and vomiting. Cancer Management: A multidisciplinary approach, 2001.
National Institutes of Health. National Cancer Institute Web site. Nausea and Vomiting (PDQ).
http://www.nci.nih.gov/cancerinfo/pdq/supportivecare/nausea/patient/#Section_13

During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting. The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.

ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.

This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.